Intensive adjuvant therapy for BRCA-related triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests an intensive add-on treatment for people with triple-negative breast cancer and a BRCA mutation who are at high risk of recurrence after surgery and standard treatments. The goal is to see if extra therapy helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have triple-negative breast cancer with a BRCA1 or BRCA2 gene mutation.
- Your cancer should have been surgically removed and must not have spread to distant organs on imaging.
- You should have a good performance status (able to do daily activities with little or no help).
- Your cancer either did not fully respond to pre-surgery treatment or was considered high-risk after surgery (tumor >2 cm or lymph node involvement).
- You must have completed all recommended chemotherapy and/or radiation after surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if additional treatment after surgery helps prevent breast cancer from returning. It is for people with hormone receptor-positive, HER2-negative breast cancer who have a BRCA1 or BRCA2 gene mutation and a high risk of recurrence.
This trial tests whether adding more treatment after surgery can help people with triple-negative breast cancer who still have cancer cells left after initial chemotherapy and immunotherapy. It aims to reduce the chance of cancer coming back.
This trial tests whether adding an experimental drug called INBRX-106 to the standard immunotherapy (pembrolizumab) and chemotherapy before surgery can improve outcomes for patients with early-stage triple-negative breast cancer. The goal is to shrink the tumor and potentially reduce the risk of the cancer coming back.
This trial tests whether people with early stage triple-negative breast cancer and a high level of immune cells in the tumor can safely skip chemotherapy after surgery. It aims to find a less intensive treatment option for those who may not need strong drugs.
This trial tests whether adding a PARP inhibitor or capecitabine (chemo) to a PD-1 inhibitor (immunotherapy) after surgery helps prevent triple-negative breast cancer from coming back. It's for people with high-risk disease who have completed initial treatment.
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
Hear when a new Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.